NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Today, EMED Technologies, a global leader in drug delivery and infusion therapy innovation, today announced the issuance of U.S. Patent No. 12,403,243 that ...
Two studies discussed the feasibility of different parameters for the infusion of a product for patients with primary immunodeficiency disorder in abstracts prepared for the American Academy of ...
Medical Device Network on MSN
KORU Medical receives FDA clearance for FreedomEDGE infusion system
Rystiggo is administered weekly, 3ml to 6ml over 15 to 30 minutes for six weeks.
SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...
PARAMUS, N.J. (May 18, 2023) – An Octapharma-sponsored study published recently in The Journal of Clinical Immunology concludes that cutaquig ® (Immune Globulin Subcutaneous [Human]-hipp, 16.5% ...
image: Octapharma USA presented research at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting evaluating the efficacy and safety of cutaquig® (Immune Globulin Subcutaneous ...
Please provide your email address to receive an email when new articles are posted on . One of my highly intelligent residents recently inquired about my personal fluidic settings for our phaco ...
The global elastomeric infusion pumps growth is driven by rising demand for home-based care, ambulatory treatment, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results